CL2008002320A1 - Método para identificar una proteína de streptococus uberis que sea capaz de producir una respuesta inmune en contra de a lo menos dos cepas de streptococcus uberis. - Google Patents

Método para identificar una proteína de streptococus uberis que sea capaz de producir una respuesta inmune en contra de a lo menos dos cepas de streptococcus uberis.

Info

Publication number
CL2008002320A1
CL2008002320A1 CL2008002320A CL2008002320A CL2008002320A1 CL 2008002320 A1 CL2008002320 A1 CL 2008002320A1 CL 2008002320 A CL2008002320 A CL 2008002320A CL 2008002320 A CL2008002320 A CL 2008002320A CL 2008002320 A1 CL2008002320 A1 CL 2008002320A1
Authority
CL
Chile
Prior art keywords
streptococcus uberis
protein
producing
strains
immune response
Prior art date
Application number
CL2008002320A
Other languages
English (en)
Spanish (es)
Inventor
Hilda Elizabeth Smith
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of CL2008002320A1 publication Critical patent/CL2008002320A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
CL2008002320A 2007-08-06 2008-08-06 Método para identificar una proteína de streptococus uberis que sea capaz de producir una respuesta inmune en contra de a lo menos dos cepas de streptococcus uberis. CL2008002320A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113844A EP2023143A1 (en) 2007-08-06 2007-08-06 Immunogenic streptococcus proteins

Publications (1)

Publication Number Publication Date
CL2008002320A1 true CL2008002320A1 (es) 2009-09-25

Family

ID=38890252

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002320A CL2008002320A1 (es) 2007-08-06 2008-08-06 Método para identificar una proteína de streptococus uberis que sea capaz de producir una respuesta inmune en contra de a lo menos dos cepas de streptococcus uberis.

Country Status (19)

Country Link
US (1) US20100297183A1 (https=)
EP (3) EP2023143A1 (https=)
JP (2) JP5462164B2 (https=)
KR (1) KR20100063706A (https=)
CN (1) CN101821627A (https=)
AR (1) AR067830A1 (https=)
AU (1) AU2008284491A1 (https=)
BR (1) BRPI0815604A2 (https=)
CA (1) CA2695721A1 (https=)
CL (1) CL2008002320A1 (https=)
CO (1) CO6270172A2 (https=)
DK (1) DK2183597T3 (https=)
ES (1) ES2432407T3 (https=)
MX (1) MX2010001482A (https=)
RU (1) RU2518315C2 (https=)
TW (1) TW200911999A (https=)
UA (1) UA103885C2 (https=)
WO (1) WO2009020391A1 (https=)
ZA (1) ZA201000806B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000005378A2 (en) 1998-07-22 2000-02-03 Id-Lelystad Instituut Voor Dierhouderij En Diergezondheid B.V. Streptococcus suis vaccines and diagnostic tests
WO2002061070A2 (en) 2001-02-02 2002-08-08 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Environmentally regulated genes, involved in the virulence of streptococcus suis
GB0818231D0 (en) * 2008-10-06 2008-11-12 Univ Nottingham Composition
KR101943171B1 (ko) 2013-09-19 2019-01-29 조에티스 서비시즈 엘엘씨 유성 아쥬반트
JP2018504381A (ja) * 2014-12-22 2018-02-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 細胞透過性ペプチド
EP3365003A1 (en) 2015-10-21 2018-08-29 Minervax APS Immunogenic fusion protein
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
RU2685957C2 (ru) * 2016-12-28 2019-04-23 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Химерный рекомбинантный белок, обладающий протективными свойствами в отношении Streptococcus pyogenes
CA3196872A1 (en) * 2020-12-23 2022-06-30 Chan Zuckerberg Biohub, Inc. Bacteria-engineered to elicit antigen-specific t cells
CN112773891B (zh) * 2021-02-01 2022-03-25 北部湾大学 卵形鲳鲹源无乳链球菌dna疫苗及其制备方法和应用
CN119219752B (zh) * 2024-09-12 2026-04-03 华中农业大学 一种猪链球菌抗原蛋白及其筛选方法及其应用
CN119780429B (zh) * 2024-12-27 2025-12-26 华派生物技术(集团)股份有限公司 一种提高猪圆环病毒2型Cap蛋白抗原琼扩检测灵敏度的方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283507A (en) 1990-12-20 1994-02-01 General Electric Company Regenerative braking protection for an electrically-propelled traction vehicle
NL9100510A (nl) * 1991-03-21 1992-10-16 Centraal Diergeneeskundig Inst Dna-sequenties die coderen voor kenmerken van virulentie van streptococcus suis en delen daarvan, daarvan afgeleide polypeptiden en antilichamen, alsmede toepassing daarvan bij de diagnose van en de bescherming tegen infectie met s. suis bij zoogdieren, waaronder de mens.
IT1251435B (it) 1991-09-04 1995-05-09 Sclavo Spa Vettore genetico per la integrazione multipla stabile di sequenze di dna nel genoma dei lieviti kluyveromyces lactis e saccharomyces cerevisiae e plasmidi che lo contengono.
US5928900A (en) * 1993-09-01 1999-07-27 The Rockefeller University Bacterial exported proteins and acellular vaccines based thereon
EP0804582A1 (en) * 1994-05-16 1997-11-05 The Uab Research Foundation $i(STREPTOCOCCUS PNEUMONIAE) CAPSULAR POLYSACCHARIDE GENES AND FLANKING REGIONS
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
EP0750042A1 (fr) * 1995-06-20 1996-12-27 Societe Des Produits Nestle S.A. Bactéries lactiques produisant des exopolysaccharides
JP4108126B2 (ja) 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
WO2000005378A2 (en) * 1998-07-22 2000-02-03 Id-Lelystad Instituut Voor Dierhouderij En Diergezondheid B.V. Streptococcus suis vaccines and diagnostic tests
ES2322306T3 (es) * 1998-12-21 2009-06-18 Medimmune, Inc. Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
WO2000077178A1 (en) * 1999-06-16 2000-12-21 Boston Biomedical Research Institute IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
DE60136356D1 (de) * 2000-06-12 2008-12-11 Univ Saskatchewan Chimäres GapC Protein aus Streptococcus und dessen Verwendung zur Impfung und Diagnostik
EP1205552A1 (en) * 2000-11-09 2002-05-15 ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. Virulence of streptococci, involving ORFs from Streptococcus suis
WO2002061070A2 (en) * 2001-02-02 2002-08-08 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Environmentally regulated genes, involved in the virulence of streptococcus suis
BR0316635A (pt) * 2002-11-26 2005-10-11 Univ Tennessee Res Foundation Molécula de aderência de streptococcus uberis
EP1590368B1 (en) * 2003-01-27 2014-02-26 Københavns Universitet Compounds useful in the diagnosis and treatment of pregnancy-associated malaria
EP2327720A1 (en) * 2003-05-30 2011-06-01 Intercell AG Enterococcus antigens
WO2006048763A1 (en) * 2004-11-05 2006-05-11 Pharmacia & Upjohn Company Llc Anti-bacterial vaccine compositions
HUE030269T2 (en) * 2006-06-26 2017-04-28 Macrogenics Inc FC RIIB-specific antibodies and methods for their use

Also Published As

Publication number Publication date
JP5462164B2 (ja) 2014-04-02
JP2014095721A (ja) 2014-05-22
CA2695721A1 (en) 2009-02-12
AU2008284491A1 (en) 2009-02-12
DK2183597T3 (da) 2013-10-14
BRPI0815604A2 (pt) 2015-03-03
AR067830A1 (es) 2009-10-21
EP2183597A1 (en) 2010-05-12
EP2183597B1 (en) 2013-07-24
CN101821627A (zh) 2010-09-01
MX2010001482A (es) 2010-03-01
UA103885C2 (en) 2013-12-10
KR20100063706A (ko) 2010-06-11
RU2010107878A (ru) 2011-09-20
US20100297183A1 (en) 2010-11-25
ZA201000806B (en) 2010-10-27
WO2009020391A1 (en) 2009-02-12
JP2010535500A (ja) 2010-11-25
EP2023143A1 (en) 2009-02-11
CO6270172A2 (es) 2011-04-20
EP2660604A3 (en) 2014-02-12
EP2660604A2 (en) 2013-11-06
TW200911999A (en) 2009-03-16
RU2518315C2 (ru) 2014-06-10
ES2432407T3 (es) 2013-12-03

Similar Documents

Publication Publication Date Title
CL2008002320A1 (es) Método para identificar una proteína de streptococus uberis que sea capaz de producir una respuesta inmune en contra de a lo menos dos cepas de streptococcus uberis.
AR082630A1 (es) Anticuerpos anti-tenascina-c a2 y metodos de uso
CL2012000429A1 (es) Uso de cepas de bifidobacterium longum para la elaboracion de una completa composicion que sirve para reducir los sintomas de alergias.
CO2019000099A2 (es) Composiciones que comprenden cepas bacterianas
CR20120011A (es) Inhibidores de bace
EA201170381A1 (ru) Получение сквалена из гиперпродуцирующих дрожжей
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
BR112015024308B8 (pt) Método para a produção de polissacarídeos e método para a produção de um composto orgânico
DOP2010000328A (es) Inhibidores de bace
CR20160570A (es) Anticuerpos anti-pld1 y su uso para mejorar la función de las celulas t
AR087113A1 (es) Metodo de cementado y composicion
AR110128A2 (es) Compuesto del grupo de las 3-(imidazoil)-pirazolo[3,4-b]piridinas, composición farmacéutica que lo comprende y método para preparar el mismo
AR074985A1 (es) Bacterias etanologenicas y su uso en la produccion de etanol
CL2011001993A1 (es) Composicion inmunogenica que comprende al menos un antigeno del virus del dengue inactivado y un adyuvante sin aluminio; metodo de produccion; y su uso para prevenir, mejorar o tratar una enfermedad productiva por el virus del dengue en un sujeto.
BR112015004515A2 (pt) composição imunogênica
BR112013025424A2 (pt) processos para produzir uma composição imunogênica, e para fabricar uma vacina, e, composição imunogênica
CR11859A (es) Composición y proceso-356
BR112013010169A8 (pt) uso de monascus na produção de ácido orgânico.
BR112015008824A2 (pt) linhagens melhoradas de microalgas e processo das mesmas
BR112012028559A2 (pt) composições biocidas, e, uso de ésteres de oligoglicerol alcoxilados
BR112017007459A2 (pt) aluminossilicato
BR112018000074A2 (pt) micro-organismo para produzir l-lisina e método para produzir l-lisina com o uso do mesmo
CR8638A (es) Vacuna agalactiae estreptococos
BR112018072511A2 (pt) métodos para selecionar uma cepa bacteriana e para profilaxia, inibição e/ou tratamento de uma alergia, cepa, e, composição antialérgica
EA200900780A1 (ru) Аналоги эпотилона, модифицированные в положениях c12-c13, как противораковые лекарственные средства